TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05949229

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine 60 MG
Description: Patients will recieve 2-hour preoperative duloxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 MG
Description: Patients will recieve 2-hour preoperative duloxetine
Study: NCT05649995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain science education driven physiotherapy program
Description: Pain science training will be carried out as described by Moseley and Butler. Topics covered within the scope of pain science education are planned to include: neurophysiology of pain, synapses, peripheral sensitization, central sensitization, plasticity of the nervous system. The aim of the training will be to teach participants that pain is a multifactorial experience rather than just tissue injury. Participants in this group will be told about the importance of physical activity integrated with pain science education (i.e., explaining that physical activity is the key to bioplasticity and causing changes in our system) and why sedentary behaviors should be reduced (reducing sedentary behaviors reduces the overprotectiveness of the pain system).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomedical education driven physiotherapy program
Description: Participants in this group will be planned to increase their knowledge of knee anatomy, knowledge of knee OA and knee OA risk factors, and the importance of increasing physical activity and reducing sedentary behavior in reducing osteoarthritic pain and improving overall health. The importance of physical activity by integrating it with biomedical education (as physical activity can help strengthen muscles, protect joint function, and improve sleep and general health) and the necessity of reducing sedentary behaviors will be discussed within the framework of biomedical education.The main difference of standard education from pain science education will be that it does not contain information about pain mechanisms mentioned in pain science education.
Study: NCT05657574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D377
Description: oral, once daily, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-331
Description: oral, once daily, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-331
Description: oral, once daily, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D086
Description: oral, once daily, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for D377)
Description: oral, once daily, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for D377)
Description: oral, once daily, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for CKD-331)
Description: oral, once daily, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for CKD-331)
Description: oral, once daily, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for D086)
Description: oral, once daily, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for D086)
Description: oral, once daily, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for D086)
Description: oral, once daily, 8 weeks
Study: NCT05380479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: mirtazaine15 mg tablet daily for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate
Description: megestrol acetate 160 mg tablet daily for 8 weeks.
Study: NCT06116513

Intervention type: DEVICE
Intervention: S53P4 bioactive glass granules
Description: During revision surgery, all infectious material would be removed and subsequently the posterior wall of the external ear canal would be reconstructed and the mastoid would be obliterated using S53P4 bioactive glass.
Study: NCT06372236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UTAA06 injection for treatment of advanced malignant solid tumors
Description: The subjects who sign the informed consent forms and been screened by inclusion/exclusion criteria,will be assigned into 1×10\^8CAR+gdT、3×10\^8CAR+gdT、5×10\^8CAR+gdT、8×10\^8CAR+gdT、1×10\^9CAR+gdT groups inder of sequence.And the subjects will be administered once.
Study: NCT06531551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The group to which Acupressure will be applied in each fraction
Description: Acupressure application protocol will be started after patient information. This process is planned to take 30 minutes.Before the application, approximately 20 seconds of warming and rubbing without direct pressure on the acupressure points will be performed to reduce tissue sensitivity and prepare the points for acupressure. Subsequently, the researcher will apply pressure with the thumb on the predetermined acupressure points, considering the individual's pain threshold, with 10 seconds of pressure followed by two seconds of relaxation without lifting the finger, in consecutive presses following the rhythm of breathing. A digital clock (belonging to the researcher) will be used to determine the duration of the acupressure application.
Study: NCT00742833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC-7483

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05987995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial injury
Description: A pipelle endometrial sampler was introduced gently into the uterine cavity. The inner piston of the catheter was withdrawn to create suction, and injury (scratching) of the endometrium was done by moving the pipelle catheter up and down within the uterine cavity
Study: NCT05403216

Intervention type: OTHER
Intervention: no intervention
Study: NCT04856839

Intervention type: DIAGNOSTIC_TEST
Intervention: high throughput sequencing and electromyography
Description: Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics

Intervention type: DIAGNOSTIC_TEST
Intervention: high throughput sequencing and electromyography
Description: Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics

Intervention type: DIAGNOSTIC_TEST
Intervention: high throughput sequencing and electromyography
Description: Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
Study: NCT05818969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis Therapy
Description: Pre-recorded hypnosis therapy audio recording with accompanying visual of a calming ocean scene to be played at least once daily for 7 days preoperatively.
Study: NCT04201808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide 25 MG
Description: All patients will receive Tenofovir Alafenamide, 25mg PO, to treat chronic hepatitis B and their previous suboptimal response over the study duration of 48 weeks. Patients will be followed every 12 weeks for medication adherence, medication refill, and follow up as per standard of care.
Study: NCT06436599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: plane block with %0.25 30 ml bupivacaine
Description: evaluation of the efficacy of two different plan blocks for postoperative anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: plane block with %0.25 30 ml bupivacaine
Description: evaluation of the efficacy of two different plan blocks for postoperative anaesthesia
Study: NCT06053190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sentence stimulus
Description: The sentences are designed such that a specific target word is either (a) Plausible (normal), (b) a semantic pragmatic violation, or (c) a morpho-syntactic violation. Example: e.g., Every morning at breakfast, the boys would (A: EAT)/ (B.PLANT )/ (C. EATS ) eggs...

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speaking style
Description: The sentences will be presented either in A. conversational speaking style, or B. hyper-articulated clear speech style. Clear and conversational speech samples will be elicited from a single male talker. In the conversational speech condition, which will be recorded first, the talker will be instructed to read the sentences as they would in everyday conversation. In the clear speech condition, the talker will be instructed to produce the sentences as if they would if they were talking to a person with hearing loss.
Study: NCT05526404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dieta mobile application
Description: Mobile application that functions on mobile phones and allows for tracking of symptoms, dietary intake, and stool characteristics using logs and pictures. Users of the application track symptoms by completing questionnaires regarding stool frequency, consistency, and mental status changes. Users can track dietary intake and stool characteristics by taking time-stamped photos of all dietary intake and bowel movements.
Study: NCT04890041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPO-RA
Description: The subjects will receive an initial dose of TPO-RA once daily. Platelet counts were collected weekly until week 6 of the study. Dosage was adjusted to maintain platelet levels between 50×10\^9/L and 150×10\^9/L according to platelet count. TPO-RA was administered once a day for 4 weeks. If the platelet count dose not reach 30×10\^9/L, the treatment was stopped. If the platelet count is more than 400×10\^9/L after taking TPO-RA once a day for 2 consecutive weeks, the treatment will be stopped.
Study: NCT05181189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB+Omega-3
Description: The omega-3 fatty acids dose will be adjusted every 8 weeks according to clinical evaluation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DAOIB+Placebo
Description: Placebo
Study: NCT05237089

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: Regular acupuncture will be applied at the main and the additional acupoints with 0.25mm\*40mm or 0.30mm\*75mm needles. The main acupoints include Shangwan (CV13), Zhongwan (CV12), Jianli (CV11), Xiawan (CV10), bilateral Quchi (LI11), Hegu (LI4), Liangmen (ST21), Tianshu (ST25), Daheng (SP15), Fujie (SP14), Shuidao (ST28), Zusanli (ST36), Fenglong (ST40), Wailing (ST26), Guilai (ST29). Additional acupoints include bilateral Shangjuxu (ST37) and Neiting (ST44), bilateral Yinlingquan (SP9) and Shuifen (CV9), Qihai (CV6) and Guanyuan (CV4). Acupuncturists will use all main acupoints and choose the combined acupoints based on the patients' patterns during each treatment session. The EA apparatus will be connected to the needles at the bilateral ST21, ST25, SP15, using continuous wave type, frequency at 3 Hz, and intensity of 4-5 mA based on the endurance of each patient. Needles will be retained for 30 minutes before removal.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Patients will receive superficial acupuncture treatment at the same main acupoints as EA group with 0.22\*0.25mm needles. The electroacupuncture apparatus will connected to the needles at the bilateral Liangmen (ST21), Tianshu (ST25), Daheng (SP15) without current output. Needles will be retained for 30 minutes before removal. The treatment will be given 3 times a week in week 1-12, 2 times a week in week 13-20, and once a week in week 21-24, totaling 56 sessions of real or sham acupuncture.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: The health management brochure will be distributed to all patients in the trial after enrollment, and health education will be arranged online or offline at week 4, 8, 12, 16, 20 and 24 for about 60 minutes, including lifestyle, diet and physical activity. According to the specific situation of each patient, healthier individual lifestyle and behavior will be recommended to all patients, but there will be no strict restrictions on the diet or physical activity.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Health education
Description: The health management brochure will be distributed to all patients in the trial after enrollment, and health education will be arranged online or offline at week 4, 8, 12, 16, 20 and 24 for about 60 minutes, including lifestyle, diet and physical activity. According to the specific situation of each patient, healthier individual lifestyle and behavior will be recommended to all patients, but there will be no strict restrictions on the diet or physical activity.
Study: NCT05172934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-arterial tenecteplase
Description: intra-arterial drug administered after mechanical thrombectomy
Study: NCT05317117

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and NxTek™ Malaria P.f/P.v RDT
Description: The NxTek (TM) Malaria Pf Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and pLDH on a single test line of Pf malaria in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.~The NxTek (TM) Malaria Pf/Pv Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) of Plasmodium falciparum (Pf) on one test line and of pLDH of Plasmodium vivax (Pv) malaria on a second test line in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.
Study: NCT04744090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: 1. Roflumilast 500 mcg daily for up to 28 days~2. Total follow up time will be 28 days.~3. Proinflammatory parameters will be assessed at baseline, day 7, day 14, and at the end of treatment.~4. Roflumilast will be combined with standard of care for ARDS.~5. During hospitalization, clinical and laboratory data will be recorded daily in the medical history of the patient and in data collection table of the study.~6. During hospitalization, adverse drug reaction will be monitored clinically and by laboratory tests.~7. In case of an adverse effect or a need to discontinue the treatment, roflumilast should be suspended.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (identical to roflumilast dosage form) will be used for placebo-comparator group.
Study: NCT05065411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enobosarm & Abemaciclib Combo
Description: Subjects will receive a combo of Enobosarm \& Abemaciclib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
Description: Non-steroidal AI, a steroidal AI (exemestane with or without everolimus), OR fulvestrant
Study: NCT04727489

Intervention type: GENETIC
Intervention: DNA from subjects will be stored in the biobank of our study.
Description: Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders.

Intervention type: GENETIC
Intervention: DNA from subjects will be stored in the biobank of our study.
Description: Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders.

Intervention type: GENETIC
Intervention: DNA from subjects will be stored in the biobank of our study.
Description: Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders.

Intervention type: GENETIC
Intervention: DNA from subjects will be stored in the biobank of our study.
Description: Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders.
Study: NCT05366868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin
Description: Imeglimin 1000 mg orally twice daily in the morning and evening (2000 mg daily).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg orally twice daily in the morning and evening (1000 mg daily). However, until 2 weeks after the start of treatment, 250 mg should be administered orally twice daily in the morning and evening. Thereafter, after 4, 8, or 12 weeks, the dose may be increased up to 750 mg twice daily (1500 mg daily) if the physician determines that the hypoglycemic effect is inadequate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: Vildagliptin 50 mg orally twice daily in the morning and evening (100 mg daily).
Study: NCT05194579

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: PF-06881894 by on-body injector
Description: PF-06881894 given by on-body injector (OBI), 6 mg administered as a single SC injection

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: PF-06881894 by prefilled syringe
Description: PF-06881894 given by prefilled syringe (PFS), 6 mg administered as a single SC injection
Study: NCT06112106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intelligent Physical Exercise Training (IPET)
Description: The intervention group will follow an Intelligent Physical Exercise training (IPET) program delivered via a mobile phone app. The scope of the physical exercise program is 50 minutes per week, and it is individually tailored according to questionnaire responses about work profile, physical capacity, health status and extent of musculoskeletal pain.
Study: NCT05387434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program-Remote (DPP-R)
Description: The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Zoom.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program-Facebook (DPP-FB)
Description: The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Facebook.
Study: NCT05541796

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraocular lens
Description: Tecnis Symfony Optiblue (Johnson \& Johnson Vision, Santa Ana, CA, Unites States) is a violet light filtering extended depth of focus IOL that provides a continuous range of clear vision at far and intermediate.~Tecnis Synergy™ IOL (Johnson \& Johnson Vision, Santa Ana, CA, Unites States) is another latest United States Food and Drug Administration (USFDA) approved IOL, designed to provide good acuity at far through near distances, reducing the need for spectacles.
Study: NCT05322668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (812A-v1), (812C-v1), (812D-v1) and (812F-v1)
Description: All the subjects will receive all the treatment in the same order.~On each hand 2 devices will be attributed as follow:~* Prototypes (812A-v1) will be applied on an area of the back of the patient's right hand, on healthy skin~* Prototypes (812C-v1) will be applied on an area of the back of the patient's right hand, on healthy skin~* Prototypes (812D-v1) will be applied on an area of the back of the patient's left hand, on healthy skin~* Prototypes (812F-v1) will be applied on an area of the back of the patient's left hand, on healthy skin
Study: NCT05613062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Huang-Lian-Jie-Du Decoction (MHLJDD)
Description: Chinese medicine granules for 12 weeks twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules for 12 weeks twice daily
Study: NCT05805319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: increasing total fiber intake
Description: Patients in the intervention arm will complete a dietary survey and be counselled on increasing their total fiber intake.
Study: NCT06473038

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduction in Salt and Sugar
Description: 150 participants who are grouped under interventions, their data will be collected according to the alterations of sodium and sugar intake and then compared with the control group. Instruments include urine analysis, providing two spot urine samples - first-morning void and last void in the evening before leaving campus, at three-time points - at the start of the study, after 3 months, and after 6 months. This will yield a total of 300 × 2 × 3 = 1800 samples. Urine electrolytes (sodium, potassium, chloride) and creatinine will be measured using the potentiometry method (Alinity Abbott) at the laboratory department of Sunway Medical Centre, Bandar Sunway.

Intervention type: DEVICE
Group type: OTHER
Intervention: The potentiometer
Description: The potentiometer is utilized for the quantitative analysis of electrolytes present in urine samples. The potentiometer used for urine electrolytes analysis is a specialized device equipped with electrodes and sensors designed to detect and measure the concentration of specific electrolytes in urine samples. It employs potentiometric principles to generate electrical signals proportional to the concentration of ions present in the sample.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Ashing Method Followed by Flame Atomic Absorption Spectrometry (FAAS)
Description: Dry ashing method involves heating the food samples in a controlled environment to remove organic matter and moisture, leaving behind inorganic residues (ashes) containing the salts and minerals present in the food. Flame Atomic Absorption Spectrometryis utilized to measure the levels of sodium and potassium (components of salt) as well as carbon and hydrogen (components of sugar) in the ashed food samples.~By determining the concentrations of these elements, the salt and sugar content of the food samples can be quantified accurately.
Study: NCT03778164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast Track Partner Services-Sexual Health Intervention
Description: The Partner Services-Sexual Health Intervention enhances the current standard of care by introducing four service innovations to the DOHMH Partner Services program: (1) enhanced field-based combination HIV and STI testing; (2) immediate field-based ARV/PrEP start; (3) navigation to a sexual health clinic for test results and treatment; and (4) enhanced linkage support to facilitate ongoing PrEP or HIV care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Partner Services Standard of Care
Description: Participants in neighborhoods that have not yet been assigned to the intervention condition in the stepped wedge trial will receive standard Partner Services components, including field-based HIV testing and referral to clinical sites for HIV prevention or treatment.